RARE - Company ID 0001515673
The table below shows Ultragenyx Pharmaceutical Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $673.00M | $560.00M | $434.00M | $363.33M | $351.41M | $271.03M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $750.00M | $698.00M | $648.00M | $705.79M | $497.15M | $412.08M |
| SG&A |
Ultragenyx Pharmaceutical Inc. reported annual revenue of $673.00M for fiscal year 2025. That is up 20.2% from $560.00M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $133.00K (FY 2016) to $673.00M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $349.00M |
| $321.00M |
| $310.00M |
| $278.14M |
| $219.98M |
| $182.93M |
| Operating income | -$535.00M | -$536.00M | -$569.00M | -$648.92M | -$381.74M | -$330.12M |
| Income tax | $4.00M | $2.00M | -$2.00M | $5.70M | $1.04M | $1.21M |
| Net income | -$575.00M | -$569.00M | -$607.00M | -$707.42M | -$454.02M | -$186.57M |
| EPS (diluted) | -$5.83 | -$6.29 | -$8.25 | -$10.12 | -$6.70 | -$3.07 |